G. A. Masters, L. Krilov, and H. H. Bailey, Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology, J Clin Oncol, vol.33, issue.7, pp.786-809, 2015.

M. A. Postow, M. K. Callahan, and J. D. Wolchok, Immune checkpoint blockade in cancer therapy, J Clin Oncol, vol.33, issue.17, pp.1974-1982, 2015.

S. L. Topalian, M. Sznol, and D. F. Mcdermott, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, vol.32, issue.10, pp.1020-1030, 2014.

A. W. Griffioen, L. A. Mans, and A. M. De-graaf, Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients, Clin Cancer Res, vol.18, issue.14, pp.3961-3971, 2012.

R. Iacovelli, F. Massari, and L. Albiges, Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma, Eur Urol, vol.68, issue.1, pp.154-160, 2015.

G. Thanarajasingam, J. M. Hubbard, and J. A. Sloan, The imperative for a new approach to toxicity analysis in oncology clinical trials, J Natl Cancer Inst, vol.107, issue.10, 2015.

A. Grothey, S. George, and E. Van-cutsem, Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care, Oncologist, vol.19, issue.6, pp.669-680, 2014.

M. Iijima, K. Fukino, and M. Adachi, Sorafenib-associated hand-foot syndrome in Japanese patients, J Dermatol, vol.38, issue.3, pp.261-266, 2011.

L. Vine, D. B. Coleman, T. A. Davis, and C. H. , Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma, Am J Clin Oncol, vol.33, issue.3, pp.217-220, 2010.

J. Peron, D. Maillet, and H. K. Gan, Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review, J Clin Oncol, vol.31, issue.31, pp.3957-3963, 2013.

S. Sivendran, A. Latif, and R. B. Mcbride, Adverse event reporting in cancer clinical trial publications, J Clin Oncol, vol.32, issue.2, pp.83-89, 2014.

D. Maillet, J. Y. Blay, and B. You, The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members, Ann Oncol, vol.27, pp.192-198, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812694

J. P. Ioannidis, S. J. Evans, and P. C. Gotzsche, Better reporting of harms in randomized trials: an extension of the CONSORT statement, Ann Intern Med, vol.141, issue.10, pp.781-788, 2004.

K. F. Schulz, D. G. Altman, and D. Moher, statement: updated guidelines for reporting parallel group randomised trials, PLoS Med, vol.7, issue.3, p.1000251, 2010.

S. M. Bentzen, W. Dorr, and M. S. Anscher, Normal tissue effects: reporting and analysis, Semin Radiat Oncol, vol.13, issue.3, pp.189-202, 2003.

R. J. Motzer, T. E. Hutson, and D. Cella, Pazopanib versus sunitinib in metastatic renalcell carcinoma, N Engl J Med, vol.369, issue.8, pp.722-731, 2013.

D. Couper and M. S. Pepe, Modelling prevalence of a condition: chronic graft-versushost disease after bone marrow transplantation, Stat Med, vol.16, issue.14, pp.1551-1571, 1997.

R. Lancar, A. Kramar, and C. Haie-meder, Non-parametric methods for analysing recurrent complications of varying severity, Stat Med, vol.14, issue.24, pp.2701-2712, 1995.

R. D. Gelber, A. Goldhirsch, and C. Hurny, Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group), J Natl Cancer Inst Monogr, issue.11, pp.127-135, 1992.

S. Patil, R. A. Figlin, and T. E. Hutson, Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-alpha, Br J Cancer, vol.106, issue.10, pp.1587-1590, 2012.

R. W. Jang, L. Maitre, A. Ding, and K. , Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, J Clin Oncol, vol.27, issue.26, pp.4268-4273, 2009.

E. Basch, B. B. Reeve, and S. A. Mitchell, Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE), J Natl Cancer Inst, vol.106, issue.9, 2014.

A. Ravaud, S. Oudard, D. Fromont, and M. , First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG), Ann Oncol, vol.26, issue.6, pp.1123-1128, 2015.

M. Edgerly and T. Fojo, Is there room for improvement in adverse event reporting in the era of targeted therapies?, J Natl Cancer Inst, vol.100, issue.4, pp.240-242, 2008.

J. L. Beaumont, J. M. Salsman, and J. Diaz, Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma, Cancer, vol.122, issue.7, pp.1108-1115, 2016.

R. J. Cook and J. F. Lawless, The Statistical Analysis of Recurrent Events, Annals of Oncology, vol.27, pp.1638-1643, 2007.

, Utrecht; 3 Department of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam; 4 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam; 5 Department of Radiotherapy, University Medical Center Utrecht, vol.6

, Image Sciences Institute; Departments of 9 Radiology and Nuclear Medicine; 10 Surgery, University Medical Center Utrecht

, The Netherlands Cancer Institute, Amsterdam; 13 Utrecht Institute of Pharmaceutical Sciences, Clinical Pharmacology, 2016.

, Response Evaluation Criteria in Solid Tumors (RECIST) are commonly used to determine the efficacy of anti-cancer therapy in clinical trials. RECIST, however, emphasizes the value of tumor shrinkage, while many targeted agents induce prolonged tumor growth arrest. This limits its use for the detection of treatment efficacy for these more cytostatic regimens. Therefore, we designed an individualized variant of a time to progression (TTP) end point based on prospective volumetric measurements, Background: Early signs of efficacy are critical in drug development